Earnings call briefFiscal fourth-quarter 2026
Twist Bioscience TWST
Twist Bioscience sees potential for triple-digit AI order growth in fiscal 2027
CFO Adam Laponis said he expects fiscal 2027 gross margin to still expand, despite about $15 million a year of depreciation, or about 2 to 3 points of headwind.
GetSignal
On its fiscal fourth-quarter call, Twist Bioscience said its initial fiscal 2027 guidance assumes $100 million in AI drug discovery revenue, from programs it can forecast with high confidence. It said additional programs with existing and new customers are not fully reflected in that guidance.
Laponis said the company expects approximately $150 million in capital expenditures for capacity, automation and software over fiscal 2027 and fiscal 2028, plus more than $30 million in landlord-funded tenant improvements.
Quotes from the call
“Over fiscal 2027 and fiscal 2028, we expect approximately $150 million in capital expenditures for capacity, automation and software, plus more than $30 million in landlord-funded tenant improvements.”
Key facts from the call
- Expected fiscal 2027 AI drug discovery revenue assumption
- $100 million, from programs it can forecast with high confidence
- Expected fiscal 2027 and fiscal 2028 capital expenditures
- approximately $150 million for capacity, automation and software, plus more than $30 million in landlord-funded tenant improvements
- Expected fiscal 2027 depreciation on capital spending of about $75 million
- approximately $15 million a year
Source: Twist Bioscience's fiscal fourth-quarter 2026 earnings call, November 12, 2026.
Written by GetSignal with AI from the company's earnings call. How we make news
Not investment advice.
More earnings call briefs
The newest- DPC Holdings raises 2026 guidance and sets 2027 outlook
DPC · DPC Holdings · Q3 2026 call · Nov 12, 2026
- Enhanced Group expects its sports business to break even or better in 2027
ENHA · Enhanced Group Inc. Class A · Q3 2026 call · Nov 12, 2026
- Cerebras Systems says hardware mix will be closer to 50% in fourth quarter
CBRS · Cerebras Systems · Q3 2026 call · Nov 12, 2026
- Nu Holdings now expects a 2026 efficiency ratio of 19% to 19.5%
NU · Nu Holdings · Q3 2026 call · Nov 12, 2026
